Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cosibelimab - Sun Pharmaceuticals Industries

Next Previous
Drug Profile

Cosibelimab - Sun Pharmaceuticals Industries

Alternative Names: Anti PDL1 monoclonal antibody; CK 301; Cosibelimab-ipdl; TG 1501; UNLOXCYT

Latest Information Update: 23 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Checkpoint Therapeutics; TG Therapeutics Inc
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Squamous cell cancer
  • Phase III Non-small cell lung cancer
  • Phase I Cancer
  • Discontinued Chronic lymphocytic leukaemia; Lymphoma; Richter's syndrome

Most Recent Events

  • 15 Jan 2026 Launched for Squamous cell cancer (Metastatic disease, Late-stage disease) in USA (IV)
  • 30 May 2025 Checkpoint Therapeutics has been acquired by Sun Pharmaceutical Industries
  • 17 Dec 2024 Phase-I development in Cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Treatment-naive) is ongoing in Australia, New Zealand, Poland, Russia, Thailand, South Africa, Ukraine, Spain, France (NCT03212404)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top